CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
Famotidine FCT +1 moredrug
Likely dose
Famotidine FCT 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00945750
NCT00945750Phase 1Completed

A Single-Dose, Open-Label, Three-Period Crossover Study to Assess the Bioequivalence of Famotidine 20 mg Film-Coated Tablets (FCT) Compared to Famotidine 20 mg Chewable Tablets (CT) Without Water and Famotidine 20 mg Chewable Tablets (CTw) With Water (Protocol 144)

Merck Sharp & Dohme LLC·interventional·Posted Jul 24, 2009·Updated Mar 10, 2017

In Brief

A Phase 1 clinical trial evaluating Famotidine FCT and Famotidine CT for Heartburn. Completed, enrolled 30 participants.

Detailed Summary

This study will determine whether the CT formulation of famotidine taken with and without water is bioequivalent to the FCT formulation. The primary hypothesis is that the area under the concentration-time curve (AUC) and the maximum plasma concentration (Cmax) of a single dose of famotidine 20 mg CT without water are equivalent to a single dose of famotidine 20 mg FCT with water.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeartburn
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 24, 2009
Enrollment StartAug 1, 2006
Primary CompletionSep 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16.9 years ago

Interventions

Famotidine FCTdrug

Famotidine 20 mg oral film-coated tablet taken once daily

Famotidine CTdrug

Famotidine 20 mg oral chewable tablet taken once daily